FDA Approves PHESGO - Metastatic Breast Cancer Trial Talk

Special Topics

In late June, the FDA approved PHESGO (pertuzumab/ trastuzumab/ hyaluronidase-zzxf), a treatment that can be injected under the skin, to treat metastatic and early-stage HER2 positive breast cancer. Because it is given as an injection, PHESGO can be given by a healthcare professional in your home, and takes less time than an infusion.

FDA Approves PHESGO for Treatment of Patients With HER2-Positive Breast Cancer Approximately Four Months Ahead of Schedule


Last Modified on December 12, 2023



for past articles or specific information.